Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing
ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022
Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years
WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection.
The continued global scale of the COVID-19 pandemic has led to increased levels of immune pressure on the virus, which is driving the emergence of variants containing mutations associated with escape from common classes of neutralizing antibodies induced by natural infection or vaccination. Unlike most antibodies currently available under EUA, ADG20 has been shown to target an epitope that is highly conserved among clade I sarbecoviruses and that is not readily targeted by the endogenous neutralizing antibody response, said Laura Walker, Ph.D., co-founder and chief scientific officer of Adagio. Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously. Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization. ADG20 was engineered for potent and broadly neutralizing activity in anticipation of both the rapid antigenic evolution of SARS-CoV-2 and the emergence of future SARS-like viruses with pandemic potential.
ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection. We did this anticipating that SARS-CoV-2 would continue to evolve and potentially render some early therapies and vaccines obsolete, said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. Our global clinical trials are advancing with potential EUA submissions in mid-2022 for both prevention and treatment of COVID-19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID-19 pandemic.
Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20s utility in addressing this newly emerged variant of concern, including:
Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS-CoV-2 and its variants of concern.
ADG20 and Variants of ConcernThe neutralizing antibody response induced by SARS-CoV-2 infection and vaccination is dominated by three classes of receptor binding domain (RBD)-directed antibodies (Class 1, Class 2 and Class 3), which often share common escape mutations. The newly emerged Omicron (B.1.1.529) variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late-stage clinical development show they target one of these three dominant antigenic regions within the RBD.
In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS-CoV-2 infection and vaccination. Thus, unlike many other clinical-stage antibodies, which were isolated from COVID-19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS-CoV-2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant.
Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development.
About ADG20ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half-life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS-CoV-2 virus, SARS-CoV-2 variants of concern Alpha, Beta, Delta, and Gamma, other SARS-CoV-2 variants to date, and additional SARS-like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well-tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow-up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.
About Adagio TherapeuticsAdagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The companys portfolio of antibodies has been optimized using Adimabs industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagios portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit http://www.adagiotx.com.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the expected neutralizing activity of ADG20 against the Omicron variant; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the risk/benefit profile of our product candidates to patients; our manufacturing capabilities and strategy, including plans for doses available in the near future; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading Risk Factors in Adagios Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagios future reports to be filed with theSEC, including Adagios Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.
Contacts: Media Contact:Dan Budwick, 1ABDan@1abmedia.com
Investor Contact:Monique Allaire, THRUST Strategic Communicationsmonique@thrustsc.com
Link:
- Choosing Regular Food to Extend Longevity - CounterPunch.org - CounterPunch - April 18th, 2024 [April 18th, 2024]
- "I love the club, I'm really happy here" - Manchester United star opens up on life at club amid contract extension uncertainty - Sportskeeda - March 31st, 2023 [March 31st, 2023]
- Life Extension review - 7 facts you should know [APRIL 2022] - February 5th, 2023 [February 5th, 2023]
- Biomedical Research & Longevity Society - Wikipedia - January 27th, 2023 [January 27th, 2023]
- NAD+ Cell Regenerator and Resveratrol Elite - Life Extension - December 26th, 2022 [December 26th, 2022]
- FLORASSIST GI with Phage Technology - Life Extension - December 12th, 2022 [December 12th, 2022]
- Magnesium Citrate 100 mg, 100 capsules - Life Extension - November 5th, 2022 [November 5th, 2022]
- AMPK Metabolic Activator, 30 tablets - Life Extension - November 5th, 2022 [November 5th, 2022]
- Germany nuclear plants life extension approved by Cabinet - DW (English) - October 19th, 2022 [October 19th, 2022]
- Biohacking: What is it, types and hacks to try for beginners - Medical News Today - October 19th, 2022 [October 19th, 2022]
- 'Biggest day of my life': Kevin Porter Jr., Rockets react to extension - Rockets Wire - October 19th, 2022 [October 19th, 2022]
- Postharvest quality solution for tomatoes-on-the-vine - hortidaily.com - October 19th, 2022 [October 19th, 2022]
- JZZ Technologies, Inc. and Subsidiary LION Development Group, Enter into JV Agreement with affiliate of Hospitality Development Group, Inc. of Florida... - October 19th, 2022 [October 19th, 2022]
- 'I love the city': QB Zach Collaros inks 3-year contract extension to stay with Blue Bombers through 2025 - CBC.ca - October 19th, 2022 [October 19th, 2022]
- MSU-led team studying expansion of controlled environment culinary herb production across US - Michigan State University - October 19th, 2022 [October 19th, 2022]
- 60 seconds with...Wayne Dunn, Babcock International - Professional Engineering - October 19th, 2022 [October 19th, 2022]
- Wind energy operators must address these 5 areas to exploit the full value of monitoring - Windpower Engineering - October 19th, 2022 [October 19th, 2022]
- Extension shares tips for practicing fire safety in the fall - The Hartselle Enquirer - Hartselle Enquirer - October 19th, 2022 [October 19th, 2022]
- FIRST Robotics Prepares to Extend Its Reach to More Vermont Students - Seven Days - October 19th, 2022 [October 19th, 2022]
- Plant Life Cycles - Penn State Extension - October 2nd, 2022 [October 2nd, 2022]
- FDA Authorizes Shelf Life Extension for Certain Lots of Paxlovid - October 2nd, 2022 [October 2nd, 2022]
- EDF considers extending life of two UK nuclear plants due to energy crisis - The Guardian - October 2nd, 2022 [October 2nd, 2022]
- Rittenbach among Extension team professionals honored - Jamestown Sun | News, weather, sports from Jamestown North Dakota - The Jamestown Sun - October 2nd, 2022 [October 2nd, 2022]
- What is the circular economy and why is it essential for real sustainability? - Schroders - October 2nd, 2022 [October 2nd, 2022]
- 44 national and international NGOs call for renewal and expansion of truce in Yemen [EN/AR] - Yemen - ReliefWeb - October 2nd, 2022 [October 2nd, 2022]
- University City Townhomes residents now have until end of the year to find new low-income housing - The Philadelphia Inquirer - October 2nd, 2022 [October 2nd, 2022]
- New Eskom board: Business groups happy with mix of skills - News24 - October 2nd, 2022 [October 2nd, 2022]
- Full circle on the farm: Penn State alum returns to help educate Pa. growers - Pennsylvania State University - October 2nd, 2022 [October 2nd, 2022]
- Task Force: Blacks are owed hundreds of thousands - CalMatters - October 2nd, 2022 [October 2nd, 2022]
- ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director - GlobeNewswire - September 20th, 2022 [September 20th, 2022]
- Analysis: Behind Trump's media deal, a vote where only yes will do - Reuters - September 20th, 2022 [September 20th, 2022]
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 | Antibodies | News Channels - PipelineReview.com - September 20th, 2022 [September 20th, 2022]
- Action Hampshire get behind Sustainable Future Fund to reduce waste in business - Hampshire Chronicle - September 20th, 2022 [September 20th, 2022]
- Living the dream - Farm Progress - September 20th, 2022 [September 20th, 2022]
- Teck and Agnico Eagle Announce Agreement on the San Nicols Copper-Zinc Project located in Zacatecas, Mexico - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Most actively traded companies on the Toronto Stock Exchange - Winnipeg Free Press - September 20th, 2022 [September 20th, 2022]
- Giants Urged to Give Extension to 24-Year-Old Defender - Heavy.com - September 20th, 2022 [September 20th, 2022]
- Russias MiG-31 Fighter That Fired Hypersonic Missiles On Ukraine Conducted Drills In The Stratosphere - EurAsian Times - September 20th, 2022 [September 20th, 2022]
- Jaguar Mining Reports Confirmed Continuity of Mineralization at Pilar Gold Mine - Life of Mine Extension Drilling to Follow - Yahoo Finance - September 14th, 2022 [September 14th, 2022]
- Easy meals, life-saving knife skills part of West Texas Fair & Rodeo Spotlight Kitchen - Abilene Reporter-News - September 14th, 2022 [September 14th, 2022]
- Beyond Bulletproof: Why Billionaires Are Chasing Everlasting Health - Newsweek - September 14th, 2022 [September 14th, 2022]
- Did California Truly Extend the Life of Diablo Canyon? Only Time Will Tell. - JD Supra - September 14th, 2022 [September 14th, 2022]
- Youth Mental Health First Aid Trainings Offered This Fall - Iowa State University - September 14th, 2022 [September 14th, 2022]
- Finland to Extend Validity of Residence Permits for Ukrainian Refugees Under Temporary Protection - SchengenVisaInfo.com - SchengenVisaInfo.com - September 14th, 2022 [September 14th, 2022]
- Wildfire Smoke's Affect on Potato Crops Being Studied - University of Idaho - September 14th, 2022 [September 14th, 2022]
- National Weather Service Northern Indiana radar will be down beginning Monday for upgrades - WANE - September 7th, 2022 [September 7th, 2022]
- Renault Trucks Will Give New Life to Old Parts - Ward's Auto - September 7th, 2022 [September 7th, 2022]
- Stop the stigma and step in - Farm Progress - September 7th, 2022 [September 7th, 2022]
- Empire Wind and WCS Announce Extension of Historic Near Real-Time Acoustic Marine Monitoring Project In New York Bight - Business Wire - September 7th, 2022 [September 7th, 2022]
- Media Advisory: Chalk River Laboratories Officially Breaks Ground on One of the Largest Nuclear Research Facilities Ever Constructed in Canada -... - September 7th, 2022 [September 7th, 2022]
- PFAS pilot study gets yet another extension, scope and cost of another project reduced - wausaupilotandreview.com - September 7th, 2022 [September 7th, 2022]
- Predators extend deal with Bally Sports South - Awful Announcing - September 7th, 2022 [September 7th, 2022]
- WWYDW: Reactions to the Canucks' J.T. Miller extension - Canucks Army - September 7th, 2022 [September 7th, 2022]
- NASA's Artemis rocket makers explain that it's a marathon and a sprint - The Register - September 7th, 2022 [September 7th, 2022]
- Food supply chains are susceptible to fraud and adulteration more than ever, warns Kerry - Food Ingredients First - September 7th, 2022 [September 7th, 2022]
- Reprieve for The White Lady as iconic food truck gets 12-month licence extension - Stuff - September 7th, 2022 [September 7th, 2022]
- Gypsy Moth Biology & Life Cycle - University of Illinois Extension - August 30th, 2022 [August 30th, 2022]
- AgriLife's Johanna Hicks and Team Honored at 2022 National Health Outreach Conference - frontporchnewstexas.com - August 30th, 2022 [August 30th, 2022]
- Harmony Gold to maintain dividends despite facing two years of heavy capital bills - Miningmx - August 30th, 2022 [August 30th, 2022]
- Malaysian, Thai companies ink MOU to explore cooperation in Mechanised Infantry Fighting Vehicle life extension programme - The Edge Markets MY - August 30th, 2022 [August 30th, 2022]
- Coveris previews new packaging solutions targeting enhanced performance and recyclability - Packaging Europe - August 30th, 2022 [August 30th, 2022]
- KPF and heatherwick studio to extend singapore airport as cluster of lush 'neighborhoods' - Designboom - August 30th, 2022 [August 30th, 2022]
- Understanding Tax Liens. Could the IRS seize your car? - finehomesandliving.com - August 30th, 2022 [August 30th, 2022]
- Extension of Legacy Trail in Tyler to continue - Tyler Morning Telegraph - August 29th, 2022 [August 29th, 2022]
- KRUG: Extension learning opportunities around the corner - Hays Post - August 29th, 2022 [August 29th, 2022]
- Half-Life 2 VR is coming, here's how you can get it - Win.gg - August 29th, 2022 [August 29th, 2022]
- Transplant technology: United Therapeutics 3D-printing of human organs focused on every breath you take - Manchester Ink Link - August 29th, 2022 [August 29th, 2022]
- Serena Williams Interview on Leaving Tennis and Her Legacy - TIME - August 29th, 2022 [August 29th, 2022]
- Thousands of photos captured by everyday Australians reveal the secrets of our marine life as oceans warm - The Conversation - August 29th, 2022 [August 29th, 2022]
- Empathy and Solidarity: On Alejandro Varela's The Town of Babylon - lareviewofbooks - August 29th, 2022 [August 29th, 2022]
- How many people continue their stay in the UK or apply to stay permanently? - GOV.UK - August 29th, 2022 [August 29th, 2022]
- Anti-Aging Conference and Olympia Weekend Set for Back-to-Back Weekends in Vegas - Muscle & Fitness - August 15th, 2022 [August 15th, 2022]
- A son steps aboard the Eagle and into his father's world - Journal Inquirer - August 15th, 2022 [August 15th, 2022]
- Class to teach healthy living for those with chronic conditions - The Maryville Forum - August 15th, 2022 [August 15th, 2022]
- New application for disinfection of fresh-cut fruits by means ozone in the packaging - hortidaily.com - August 15th, 2022 [August 15th, 2022]
- Meatless Meats and Smokeless Smokes - Equities News - August 15th, 2022 [August 15th, 2022]
- Command & Control Success: Fireground Commander: Understanding the Impact - Firehouse - August 15th, 2022 [August 15th, 2022]
- Five Ways This Survey About Maine's Wellness is Absolutely Bogus - WJBQ - July 25th, 2022 [July 25th, 2022]
- Center for Advanced Innovation in Agriculture, Virginia Cooperative Extension help Virginia Tech showcase its land-grant mission at 2022 Virginia Ag... - July 25th, 2022 [July 25th, 2022]
- Anti-ageing tips: Here's how to rewind your biological clock - Hindustan Times - July 25th, 2022 [July 25th, 2022]